 Lipocine Inc. NASDAQ:LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities purchase agreements with certain institutional investors providing for the purchase and sale of 10,084,034 Class A Units at an offering price of 0.595 per unit, with each Class A Unit consisting of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of 0.53 per share of common stock, in a registered direct offering priced at-the-market. Gross proceeds to the Company are expected to be approximately 6 million, before deducting placement agent fees and other estimated offering expenses. The closing of the sale of the securities is expected to take place on or about February 27, 2020, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. 